Trial · NCT04205929

Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users

NCT04205929, Phase 4, Completed, Oregon Health and Science University; results first posted 2024-07-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users. Trials, record NCT04205929. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04205929

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users
NCT number: NCT04205929
Status: Completed
Phases: Phase 4
Enrollment: 58 participants, actual
Lead sponsor: Oregon Health and Science University
Conditions: Bleeding, Implants, Breakthrough Bleeding
Interventions: Placebo, Curcumin
First posted: 2019-12-20
Last updated: 2024-07-03
Results first posted: 2024-07-03

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Total Number of Days Without Bleeding or Spotting	Day 1 to Day 30	Total number of days without bleeding or spotting in the 30-day reference period
Secondary	Total Number of Bleeding/Spotting Days	Day 1 to Day 30	Total number of days with bleeding or spotting in the 30-day reference period
Secondary	Total Number of Spotting Days	Day 1 to Day 30	Total number of days with spotting in the 30-day reference period
Secondary	Total Number of Bleeding Days	Day 1 to Day 30	Total number of days with bleeding in the 30-day reference period
Other	Change in Patient Satisfaction With Bleeding Pattern as Assessed by VAS	Day 1 to Day 30	Change in the level of patient satisfaction with bleeding pattern as measured by Visual Analog Scale (VAS) from Day 1 to Day 30. The scale ranges from 0 (lowest possible satisfaction) to 100 (highest possible satisfaction).
Other	Proportion of Participants Who Intend to Continue Use of Implant	Day 30	Percentage of participants who are continuing implant use or anticipate implant continuation, evaluated at the end of study

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Total Number of Days Without Bleeding or Spotting	Day 1 to Day 30	days	MEAN
SECONDARY	Total Number of Bleeding/Spotting Days	Day 1 to Day 30	days	MEAN
SECONDARY	Total Number of Spotting Days	Day 1 to Day 30	days	MEAN
SECONDARY	Total Number of Bleeding Days	Day 1 to Day 30	days	MEAN
OTHER_PRE_SPECIFIED	Change in Patient Satisfaction With Bleeding Pattern as Assessed by VAS	Day 1 to Day 30	units on a scale	MEDIAN
OTHER_PRE_SPECIFIED	Proportion of Participants Who Intend to Continue Use of Implant	Day 30	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Total Number of Days Without Bleeding or Spotting	Placebo Group	17.5	Standard Deviation 4.8	days
Total Number of Days Without Bleeding or Spotting	Curcumin Group	16.7	Standard Deviation 6.9	days
Total Number of Bleeding/Spotting Days	Placebo Group	12.5	Standard Deviation 4.8	days
Total Number of Bleeding/Spotting Days	Curcumin Group	13.3	Standard Deviation 6.9	days
Total Number of Spotting Days	Placebo Group	4.9	Standard Deviation 3.1	days
Total Number of Spotting Days	Curcumin Group	6.7	Standard Deviation 4.3	days
Total Number of Bleeding Days	Placebo Group	7.6	Standard Deviation 4.5	days
Total Number of Bleeding Days	Curcumin Group	6.6	Standard Deviation 4.9	days
Change in Patient Satisfaction With Bleeding Pattern as Assessed by VAS	Placebo Group	9.5	Inter-Quartile Range 0.8 to 53	units on a scale
Change in Patient Satisfaction With Bleeding Pattern as Assessed by VAS	Curcumin Group	42	Inter-Quartile Range 18 to 64	units on a scale

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Group	29
Overall Study	STARTED	Curcumin Group	29
Overall Study	COMPLETED	Placebo Group	28
Overall Study	COMPLETED	Curcumin Group	26
Overall Study	NOT COMPLETED	Placebo Group	1
Overall Study	NOT COMPLETED	Curcumin Group	3

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Stomach cramps	Gastrointestinal disorders	Placebo Group	0	0	0
other	Stomach cramps	Gastrointestinal disorders	Curcumin Group	1	29	1
other	Nausea	Gastrointestinal disorders	Placebo Group	1	29	1
other	Nausea	Gastrointestinal disorders	Curcumin Group	0	29	0
other	Migraine headache	General disorders	Placebo Group	0	29	0
other	Migraine headache	General disorders	Curcumin Group	1	29	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo Group	0	29
Total, all-cause mortality	Curcumin Group	0	29
Total, other adverse events	Placebo Group	1	29
Total, other adverse events	Curcumin Group	2	29
Total, serious adverse events	Placebo Group	0	29
Total, serious adverse events	Curcumin Group	0	29

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37116825	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Curcumin Group vs Placebo Group: Proportion of Participants Who Intend to Continue Use of Implant	Trial comparisons
Curcumin Group vs Placebo Group: deaths from any cause	Trial comparisons
Curcumin Group vs Placebo Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04205929

GET https://conductscience.org/api/trials/v1/NCT04205929/registered

API reference For AI assistants